Gilead Sciences Inc.'s drug Biktarvy has been approved for the treatment of HIV-1 in China, the company said Friday. The China National Medical Products Administration approved...
Here's a roundup of top developments in the ... Full story available on Benzinga.com
Gilead Sciences (NASDAQ:GILD) and partner Galapagos (NASDAQ:GLPG) announced that the European Medicines Agency (“EMA”) has accepted their marketing authorization...
For Immediate ReleaseChicago, IL – August 14, 2019 – Today, Zacks Equity Research discusses Biomedical and Genetics, including Gilead Sciences (NASDAQ:GILD) ,...
As our understanding of the human body and the ailments that attack it continues to improve, so to do our medical approaches toward conditions of all levels of severity. While this...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Sell||Strong Sell||Sell||Strong Sell||Strong Sell|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Black Crows||30||1||Aug 16, 2019 03:00PM|
|Three Black Crows||30||2||Aug 16, 2019 02:30PM|
|Engulfing Bearish||1D||4||Aug 12, 2019|
|Three Black Crows||15||4||Aug 16, 2019 02:45PM|
|Bullish Engulfing||5H||8||Aug 13, 2019 07:00AM|
|Net 1 UEPS||3.24||3.33||3.24||-0.01||-0.31%||88.09K||16/08|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.Read More
|U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States)||$0||Start Trading|
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.